Hims & Hers Health Logo
US4330001060
A2QMYY
HIMS

Hims & Hers Health

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 28,27 € (+74,83 %). La mediana es de 29,18 € (+80,46 %).

Comprar
  7
Mantener
  13
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • JPMorgan rates Hims & Hers neutral and sees risks in shift to branded GLP‑1s

    JPMorgan initiated coverage of Hims & Hers with a neutral rating and a $32 price target for December 2027. The bank praises the rapid direct‑to‑consumer growth but sees execution risks in the strategic pivot to approved branded GLP‑1 drugs rather than compounded formulations. Hims & Hers, in partnership with Novo Nordisk, fulfilled more than 125,000 Wegovy shipments in the first six weeks; JPMorgan forecasts $1.1bn in GLP‑1 revenue for 2026 and sees long‑term potential through 2030, but requires proof of successful execution, sustainable growth in new specialty areas, and margin expansion. » Más en de.investing.com


  • Hims & Hers expands into Australia by renaming Pilot

    Hims & Hers is introducing its brand in Australia by renaming the acquired men’s health platform Pilot to Hims. Existing Pilot patients will retain their treatment plans and providers; the offering includes sexual health, weight-loss and hair-loss treatments. The company has expanded customer support to 24/7, introduced new treatment combinations and clinical pathways, and is reorganizing leadership for the market. Hims & Hers acquired Eucalyptus in early 2026; the announcement notes integration, competitive and retention risks. » Más en de.investing.com


  • Hims & Hers placed in Visa monitoring program after spike in weight-loss subscription disputes

    Visa enrolled Hims & Hers in its Acquirer Monitoring Program after dispute rates for the company’s weight-loss subscriptions exceeded Visa’s 1.5% threshold. Hims faces an ~$75,000 surcharge in September and must keep disputes below 1.5% for three consecutive months to exit the program. The action compounds regulatory pressure from a recent FTC lawsuit over billing and cancellation practices, though Hims says disputed charges are a small number and is taking corrective steps. Shares tumbled after the news despite strong subscriber growth and rising revenue alongside widening losses and margin pressure. » Más en finance.yahoo.com


  • Hims & Hers in Visa monitoring program after rise in credit card complaints

    Hims & Hers was placed in Visa's Acquirer Monitoring Program after the number of credit card complaints in its subscription business for weight-loss products exceeded allowable thresholds in July. Each complaint carries an $8 penalty fee, which, according to internal documents, could result in a bill of nearly $75,000 due in September. Visa is demanding that the complaint rate be reduced to under 1.5% of transactions for three consecutive months; Hims & Hers says the number of disputed charges is relatively small and that it has implemented measures to improve the checkout process. » Más en de.investing.com


  • Hims & Hers Health insider sells 21,500 shares to cover tax withholding after RSU vesting

    Chief legal officer Soleil Boughton reported a non‑discretionary sale of 21,500 Hims & Hers Health shares on August 14 to satisfy tax withholding tied to vested restricted stock units, raising about $605,000 at $28.15 per share. Boughton retains 339,075 directly held shares and additional vested and unvested awards. The company faces a recent FTC lawsuit (a $47.5 million legal contingency) even as revenue grew 38% last quarter and management raised full‑year guidance, while the stock is down about 40% over the past year. » Más en finance.yahoo.com

Datos financieros de la empresa

En el último trimestre, Hims & Hers Health tuvo unos ingresos de 786,07 M € y un beneficio neto de -29,17 M €
(EUR) septiembre de 2026
YoY
Ingresos 786,07 M 54,01 %
Beneficio bruto 449,55 M 19,34 %
Beneficio neto -29,17 M 317,01 %
EBITDA -7,1 M 127,87 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
3617,63 M €
Número de acciones
226,03 M
Máximo/mínimo de 52 semanas
37,38 € - 12,53 €
Dividendos No
Beta
2,50
Ratio P/E
-21,40
Ratio PEG
0,48
Ratio P/B
11,55
Ratio P/S
1,38

Perfil de la empresa

Hims & Hers Health, Inc. opera una plataforma de telemedicina multiespecializada que conecta a los consumidores con profesionales de la salud con licencia. La empresa ofrece una variedad de productos y servicios de salud y bienestar que los clientes pueden comprar directamente en sus sitios web y en su aplicación móvil. También proporciona medicamentos recetados de forma recurrente y atención continua por parte de proveedores de servicios de salud; y medicamentos y productos sin receta, dispositivos, cosméticos y suplementos, centrados principalmente en el bienestar, la salud y el bienestar sexual, el cuidado de la piel y el cuidado del cabello. Los productos no recetados seleccionados por la empresa incluyen suplementos de vitamina C, melatonina, biotina y colágeno en la categoría de bienestar; hidratante, sérums y limpiador facial en la categoría de cuidado de la piel; preservativos, spray retardante y toallitas, vibradores y lubricantes en la categoría de salud y bienestar sexual; y champús, acondicionadores, exfoliantes para el cuero cabelludo y tratamientos tópicos, como el minoxidil, en la categoría de cuidado del cabello. Además, ofrece servicios de consulta médica, así como productos de salud y bienestar a través de socios mayoristas. La empresa tiene sede en San Francisco, California.

Nombre
Hims & Hers Health
CEO
Andrew Dudum
Sede San Francisco, ca
Estados Unidos
Sitio web
Sector
Salud
Industria
Proveedores y servicios sanitarios
Salida a bolsa
13/09/2019
Empleados 2442

Símbolos bursátiles

Bolsa Símbolo
NYSE
HIMS
Frankfurt
82W.F
Düsseldorf
82W.DU
München
82W.MU
🍪

Parqet  usa cookies. Más información